Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choridal neovascularization in monkeys

Molecular Vision

Volumn 14, Issue , 2008, Pages 37-49

  Zhang, Ming ^a   Zhang, Junjun ^a   Yan, Mi ^a   Li, Hong ^b   Yang, Chun ^b   Yu, Dechao ^b  

^a SICHUAN UNIVERSITY   (China)

^b Chengdu Kanghong Biotechnology Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; KH 902; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CELL LINE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DOSE COMPARISON; ELECTRORETINOGRAPHY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ANGIOGRAPHY; GROWTH INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUVEC CELL LINE; IC 50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; NONHUMAN; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; SUBRETINAL NEOVASCULARIZATION;

ANIMALS; BINDING, COMPETITIVE; CAPILLARY PERMEABILITY; CELL PROLIFERATION; CHOROIDAL NEOVASCULARIZATION; ELECTRORETINOGRAPHY; ENDOTHELIAL CELLS; FLUORESCEIN ANGIOGRAPHY; FUNDUS OCULI; HUMANS; INJECTIONS; MACACA MULATTA; MACULA LUTEA; RECOMBINANT FUSION PROTEINS; TOMOGRAPHY, OPTICAL COHERENCE; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 38349038451     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Friedman DS, O'Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J, Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004; 122:564-72.
2. Bressler NM, Bressler SB, Congdon NG, Ferris FL 3rd, Friedman DS, Klein R, Lindblad AS, Milton RC, Seddon JM, Age-Related Eye Disease Study Research Group. Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol 2003; 121:1621-4.
3. Ferris FL, 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984; 102:1640-2.
4. Miller JW, Adamis AP, Shima DT, D'Amore PA, Moulton RS, O'Reilly MS, Folkinan J, Dvorak HF, Brown LF, Berse B, Yeo TK, Yeo KT. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994; 145:574-84.
5. Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, Folkman J, D'Amore PA, Miller JW. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996; 114:66-71.
6. Rakic JM, Lambert V, Devy L, Luttun A, Carmeliet P, Claes C, Nguyen L, Foidart JM, Noel A, Munaut C. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003; 44:3186-93.
7. Moisseiev J, Alhalel A, Masuri R, Treister G. The impact of the macular photocoagulation study results on the treatment of exudative age-related macular degeneration. Arch-Ophthalmol 1995; 113:185-9.
8. Blinder KJ, Bradley S, Bressler NM, Bressler SB, Donati G, Hao Y, Ma C, Menchini U, Miller J, Potter MJ, Pournaras C, Reaves A, Rosenfeld PJ, Strong HA, Stur M, Su XY, Virgili G, Treatment of Age-related Macular Degeneration with Photodynamic Therapy study group, Verteporfin in Photodynamic Therapy study group. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol 2003; 136:407-18.
9. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 1993; 111:1200-9.
10. Reinke MH, Canakis C, Husain D, Michaud N, Flotte TJ, Gragoudas ES, Miller JW. Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey. Ophthalmology 1999; 106:1915-23.
11. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR, VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351:2805-16.
12. Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmoiogy 2006; 113:632.e1.
13. Folkman J. Transplacental carcinogenesis by stilbestrol. N Engl J Med 197 1; 285:404-5.
14. Yamada H, Yamada E, Kwak N, Ando A, Suzuki A, Esumi N, Zack DJ, Campochiaro PA. Cell injury unmasks a latent proangiogenic phenotype in mice with increased expression of FGF2 in the retina. J Cell Physiol 2000; 185:135-42.
15. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996; 37:1929-34.
16. Krzystolik MG, Afshari MA, Adamis AP, Gaudreault J, Gragoudas ES, Michaud NA, Li W, Connolly E, O'Neill CA, Miller JW. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002; 120:338-46.
17. Spaide R. New treatments for AMD. Ophthalmology 2006; 113:160-1; authorreply 161-2.
18. Pieramici DJ, Avery RL, Castellarin AA, Nasir MA, Rabena M. Case of anterior uveitis after intravitreal injection of bevacizumab. Retina 2006; 26:841-2.
19. Benz MS, Nguyen QD, Chu K, Cahn A, Grimes I, Ingerman I, Cedarbaum JM. CLEAR-IT-2: Interim Results of the Phase II, Randomized, Controlled Dose-and Interval-Ranging Study of Repeated Intravitreal VEGF Trap Administration in Patients With Neovascular Age-Related Macular Degeneration. ARVO Annual Meeting; 2007May 6-10; Fort Lauderdale (FL).
20. Suto K, Yamazaki Y, Morita T, Mizuno H. Crystal structures of novel vascular endothelial growth factors (VEGF) from snake venoms: insight into selective VEGF binding to kinase insert domain-containing receptor but not to fins-like tyrosine kinase-1. J Biol Chem 2005; 280:2126-31.
21. Luo JC, Yamaguchi S, Shinkai A, Shitara K, Shibuya M. Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors. Cancer Res 1998; 58:2652-60.